Atossa Therapeutics held its 2024 Annual Meeting of Stockholders, where they approved an amendment and restatement of the 2020 Stock Incentive Plan, appointed a new Chief Financial Officer, and approved an amendment to increase the number of authorized shares of Common Stock.